Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment
Figure 6.
Inhibitory effect of Ruxolitinib on MPN progression; blue arrows indicate the normal JAK/STAT pathway and red arrows indicate the overactivation of the JAK/STAT pathway due to driver mutations.